← Back to Search

Hepatic Artery Embolization for Liver Cancer

Q: What is the enrollment rate for this clinical study?

<p>Affirmative. Data hosted on clinicaltrials.gov attests that this medical research, which had its inception on February 11th 2022, is presently recruiting individuals to take part in the study. Specifically, 10 volunteers are required from a single location.</p>

Q: Are there still opportunities for patient involvement in this research?

<p>Current information on clinicaltrials.gov affirms that this research is actively recruiting individuals, having been initially posted February 11th 2022 and last updated March 22nd 2022.</p>

Phase < 1

Waitlist Available

Led By Scott M Thompson

Research Sponsored by Mayo Clinic

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up up to 2 years

Awards & highlights

Study Summary

This trial is testing a new way to give the imaging agent 68Ga-PSMA to better detect prostate-specific membrane antigen (PSMA) positive liver cancer.

Eligible Conditions

Liver Cancer

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ up to 2 years

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~up to 2 years

This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 2 years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Intraindividual intralesional difference in maximum standardized uptake value (SUVmax)

Secondary outcome measures

Difference in PSMA uptake measured by SUVmax (fold change, absolute difference) in the kidneys, spleen and salivary glands between I.A. and I.V. PSMA PET.

Incidence of adverse events

Intraindividual intralesional differences in tumor to background (TBR) of SUVmax

Trial Design

1Treatment groups

Experimental Treatment

Group I: Diagnostic (embolization, 68Ga-PSMA, PET/CT)Experimental Treatment3 Interventions

Patients undergoing clinically indicated hepatic artery embolization will receive 68Ga-PSMA intraarterially (IA) over 5 minutes. After 60-90 minutes, patients undergo PET/CT scan over 1 hour.

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

Gallium Ga 68 Gozetotide

2020

Completed Phase 3

~1750

Positron Emission Tomography and Computed Tomography Scan

2015

N/A

~20

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

National Cancer Institute (NCI)NIH

13,657 Previous Clinical Trials

40,933,667 Total Patients Enrolled

104 Trials studying Liver Cancer

26,668 Patients Enrolled for Liver Cancer

Mayo ClinicLead Sponsor

3,206 Previous Clinical Trials

3,767,083 Total Patients Enrolled

4 Trials studying Liver Cancer

9,361 Patients Enrolled for Liver Cancer

Scott M ThompsonPrincipal InvestigatorMayo Clinic in Rochester

Media Library

Hepatic Artery Embolization Clinical Trial Eligibility Overview. Trial Name: NCT05111314 — Phase < 1

Liver Cancer Research Study Groups: Diagnostic (embolization, 68Ga-PSMA, PET/CT)

Liver Cancer Clinical Trial 2023: Hepatic Artery Embolization Highlights & Side Effects. Trial Name: NCT05111314 — Phase < 1

Hepatic Artery Embolization 2023 Treatment Timeline for Medical Study. Trial Name: NCT05111314 — Phase < 1

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What is the enrollment rate for this clinical study?

"Affirmative. Data hosted on clinicaltrials.gov attests that this medical research, which had its inception on February 11th 2022, is presently recruiting individuals to take part in the study. Specifically, 10 volunteers are required from a single location."

Answered by AI

Are there still opportunities for patient involvement in this research?

"Current information on clinicaltrials.gov affirms that this research is actively recruiting individuals, having been initially posted February 11th 2022 and last updated March 22nd 2022."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Comparison of Hepatic Intraarterial Versus Systemic Intravenous 68Ga-PSMA PET/CT for Detection of Hepatocellular Carcinoma

Scott M. Thompson 2022. "Comparison of Hepatic Intraarterial Versus Systemic Intravenous 68Ga-PSMA PET/CT for Detection of Hepatocellular Carcinoma". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05111314.